RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches

RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望

◆タイトル:RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches
◆商品コード:VGAIN50611
◆調査・発行会社:visiongain
◆発行日:2015年6月
◆ページ数:174
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、RNA干渉(RNAi)治療の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・RNA干渉(RNAi)治療の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・主なRNA干渉(RNAi)治療分野
・RNA干渉(RNAi)治療の製品パイプライン分析
・地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

RNAi therapies – new study showing you trends, R&D progress, and predicted revenues
When will RNAi therapies reach the market? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 174-page report provides 95 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Joseph Payne, CEO, Arcturus Therapeutics
• J. Michael French, President and CEO, Marina Biotech

See revenue forecasts for the most promising products in development
How will leading RNAi therapies perform to 2025 at world level? Our study forecasts sales of 11 products, including:
• ALN-TTR02 (patisiran)
• Vigil immunotherapy
• ALN-TTRsc (revusiran)
• ARC-520
• Atu027
• PF-655
• QPI-1002
• RXI-109
• siG12D-LODER
• SPC3649 (miravirsen)
• SYL040012

Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 4 regional markets plus the Rest of the World to 2025:
• US
• EU5
• Asia-Pacific
• Latin America
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the US, in particular, will achieve high revenue growth to 2025. Developments worldwide in biotechnology infrastructure and RNAi therapy development will influence the market.

Leading companies and potential for market growth
Overall world revenue for RNAi therapies will reach $391m in 2018, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and high unmet medical needs in many markets will increase sales to 2025.

Our work shows you what organisations hold greatest potential. See visiongain’s analysis of 11 leading companies, including these:
• Alnylam Pharmaceuticals
• Arrowhead Research
• Benitec Biopharma
• Gradalis Incorporated
• Quark Pharmaceuticals
• Roche Innovation Center Copenhagen (formerly Santaris Pharma)
• RXi Pharmaceuticals
• Silence Therapeutics
• Silenseed
• Sylentis
• Tekmira Pharmaceuticals.

A company profile gives you the following information where available:
• Historical revenues from 2010 to 2014
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas and technologies:
• Small interfering RNA (siRNA) therapies
• Short hairpin RNA (shRNA) therapies
• DNA-directed RNAi (ddRNAi) therapies
• Delivery technologies such as lipid nanoparticles and viral vectors
• Other progress in RNAi therapy development.

RNAi therapy R&D is strong in siRNA-based therapies. Novel compounds and new delivery vectors with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

【レポートの目次】

1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report

3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases – Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases – Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders – Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease – Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)

4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025

5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025

6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company’s Market Position
6.2.3.2 Arrowhead Acquires Novartis’ RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia’s CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics’ RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest

7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline

8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry’s Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors

9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics’ RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech’s RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics

10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?

11. Glossary

List of Tables
Table 1.1 Leading Regional RNAi Therapies Market Forecast 2015 ($m, AGR%)
Table 2.1 Advantages and Disadvantages of Chemically-Modified Synthetic siRNAs, 2015
Table 2.2 Advantages of ddRNAi over siRNAs, 2015
Table 2.3 Clinical Trial Phases
Table 2.4 Currency Exchange Rates, 2014
Table 3.1 RNAi Pipeline Therapies by Therapeutic Area, 2015
Table 4.1 World RNAi Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 5.1 World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 5.2 Market Shares (%) of Leading Regional RNAi Therapies Markets, 2020 and 2025
Table 5.3 US RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.4 EU5 RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Asia-Pacific RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Latin American RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Rest of the World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.1 Alnylam Pharmaceuticals: RNAi Pipeline for Genetic Medicine, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.2 Alnylam Pharmaceuticals: RNAi Pipeline for Cardio-Metabolic Disease, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.3 Alnylam Pharmaceuticals: RNAi Pipeline for Hepatic Infectious Disease, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.4 Alnylam Pharmaceuticals: Revenue from Collaborators ($m), 2012-2014
Table 6.5 Alnylam Pharmaceuticals: Revenue ($m), Revenue Share (%) from Collaborators, 2014
Table 6.6 Alnylam: Revenue ($m), AGR(%), 2010-2014
Table 6.7 Arrowhead Research: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.8 Arrowhead Research: Revenue ($m), AGR(%), 2010-2014
Table 6.9 Benitec Biopharma: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.10 Benitec Biopharma: Revenue ($m), AGR(%), 2010-2014
Table 6.11 Gradalis: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.12 Quark Pharmaceuticals: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.13 Roche: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.14 RXi Pharmaceuticals: Revenue ($m), AGR(%), 2010-2014
Table 6.15 Silence Therapeutics: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.16 Silence Therapeutics: Revenue ($m), AGR(%), 2010-2014
Table 6.17 Silenseed: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.18 Sylentis: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.19 Tekmira: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.20 Tekmira: Revenue from Collaborators ($m), 2012-2014
Table 6.21 Tekmira: Revenue ($m), Revenue Share (%) from Collaborators, 2014
Table 6.22 Tekmira: Revenue ($m), AGR(%), 2010-2014
Table 7.1 RNAi Pipeline Therapies by Phase, 2015
Table 7.2 RNAi Therapies Pipeline: Phase 3 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.3 Alnylam/Genzyme: ALN-TTR02 (patisiran) Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.4 Alnylam/Genzyme: ALN-TTRsc (revusiran) Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.5 Gradalis: Vigil Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.6 RNAi Therapies Pipeline: Phase 2 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.7 Arrowhead: ARC-520 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.8 Silence Therapeutics: Atu027 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.9 Quark: PF-655 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.10 Quark: QPI-1002 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.11 RXi: RXI-109 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.12 Silenseed: siG12D-LODER Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.13 Roche: SPC3649 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.14 Sylentis: SYL040012 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.15 RNAi Therapies Pipeline: Phase 1 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.16 RNAi Therapies Pipeline: Drugs in Preclinical Development, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 8.1 Leading Contract Manufacturing Organisations Developing Oligonucleotide APIs, 2015 (Company, Country, Link)
Table 8.2 Advantages of Local Delivery Over Systemic Delivery, 2015
Table 8.3 Leading Companies Developing RNAi Delivery Systems and Technologies, 2015 (Company, Technology, Link)
Table 8.4 Leading Companies Developing Antisense Drugs, 2015 (Company, Lead Candidate, Indication, Phase of Development)
Table 8.5 Leading Companies Developing Aptamer Drugs, 2015 (Company, Lead Candidate, Indication, Phase of Development)
Table 10.1 RNAi Therapies Late-Stage Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)

List of Figures
Figure 1.1 Number of Unique RNAi Pipeline Products by Company, 2015
Figure 2.1 Structure of RNA and DNA, 2015
Figure 2.2 RNA Interference in Protein Synthesis
Figure 2.3 Summary of the Molecular Process of RNA Interference
Figure 3.1 RNAi Pipeline Therapies by Therapeutic Area, 2015
Figure 4.1 World RNAi Therapies Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 4.2 World RNAi Therapies Market: Drivers and Restraints, 2015-2025
Figure 5.1 World RNAi Therapies Market Forecast: Revenues ($m) by Region, 2014-2025
Figure 5.2 World RNAi Therapies Market: Market Shares (%) by Region, 2020
Figure 5.3 World RNAi Therapies Market: Market Shares (%) by Region, 2025
Figure 5.4 US RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.5 EU5 RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.6 Asia-Pacific RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.7 Latin American RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.8 Rest of the World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.1 Alnylam Pharmaceuticals: Revenue Share (%) from Collaborators, 2014
Figure 6.2 Alnylam: Revenue ($m), AGR(%), 2010-2014
Figure 6.3 Arrowhead Research: Revenue ($m), AGR(%), 2010-2014
Figure 6.4 Benitec Biopharma: Revenue ($m), AGR(%), 2010-2014
Figure 6.5 RXi Pharmaceuticals: Revenue ($m), AGR(%), 2010-2014
Figure 6.6 Silence Therapeutics: Revenue ($m), AGR(%), 2010-2014
Figure 6.7 Tekmira: Revenue Share (%) from Collaborators, 2014
Figure 6.8 Tekmira: Revenue ($m), AGR(%), 2010-2014
Figure 7.1 RNAi Pipeline Therapies by Phase, 2015
Figure 7.2 Alnylam/Genzyme: ALN-TTR02 (patisiran) Revenue ($m), AGR (%), 2014-2025
Figure 7.3 Alnylam/Genzyme: ALN-TTRsc (revusiran) Revenue ($m), AGR (%), 2014-2025
Figure 7.4 Gradalis: Vigil Revenue ($m), AGR (%), 2014-2025
Figure 7.5 Arrowhead: ARC-520 Revenue ($m), AGR (%), 2014-2025
Figure 7.6 Silence Therapeutics: Atu027 Revenue ($m), AGR (%), 2014-2025
Figure 7.7 Quark: PF-655 Revenue ($m), AGR (%), 2014-2025
Figure 7.8 Quark: QPI-1002 Revenue ($m), AGR (%), 2014-2025
Figure 7.9 RXi: RXI-109 Revenue ($m), AGR (%), 2014-2025
Figure 7.10 Silenseed: siG12D-LODER Revenue ($m), AGR (%), 2014-2025
Figure 7.11 Roche: SPC3649 Revenue ($m), AGR (%), 2014-2025
Figure 7.12 Sylentis: SYL040012 Revenue ($m), AGR (%), 2014-2025
Figure 8.1 RNAi Therapies Market: Strengths and Weaknesses, 2015-2025
Figure 8.2 RNAi Therapies Market: Opportunities and Threats, 2015-2025

【レポートのキーワード】

RNA干渉(RNAi)、RNAi治療、RNAi技術、siRNA、shRNA、ddRNAi、パイプライン

★調査レポート[RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望] ( RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches / VGAIN50611) 販売に関する免責事項
[RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望] ( RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches / VGAIN50611) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆